Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence by Gu, C et al.
Low expression of polypeptide GalNAc N-acetylgalactosaminyl
transferase-3 in lung adenocarcinoma: impact on poor prognosis
and early recurrence
CG u
1, T Oyama*,2, T Osaki
2,JL i
2, M Takenoyama
2, H Izumi
3, K Sugio
2, K Kohno
3 and K Yasumoto
2
1Department of Thoracic and Cardiovascular Surgery, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China;
2Department of
Surgery II University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu 807-8555, Japan;
3Department of Molecular Biology, University of Occupational and Environmental Health, School of Medicine, 1-1 Iseigoaka, Yahatanishi-ku Kitakyushu
807-8555, Japan
Initial glycosylation of mucin-type O-linked protein is catalysed by one of the UDP-GalNAc: polypeptide N-acetyl-galactosaminyl
transferase-3 (GalNAc-T3). O-glycosylation is important in the binding of cell adhesion molecules, cell differentiation, invasion, and
metastasis in tumours. This study was designed to detect GalNAc-T3 expression in lung adenocarcinoma by using
immunohistochemical staining, and to evaluate the relationship between the GalNAc-T3 expression level and prognosis and
recurrence in completely resected lung adenocarcinoma patients. A low expression of GalNAc-T3 was detected in the cytoplasm of
tumour cells in 79 of 148 patients (53.4%) with lung adenocarcinoma. The low expression of GalNAc-T3 was associated with poorly
differentiated tumour (Po0.0001), poor pathologic stage (Po0.0001), lymph node metastasis (Po0.0001), and tumour recurrence
(P¼0.016). The lung carcinoma patients with low GalNAc-T3 expression had a poorer prognosis than those with high GalNAc-T3
expression, using both univariate and multivariate analyses (overall survival: Po0.0001 and P¼0.011, respectively). In addition,
multivariate analysis of the clinicopathological characteristics of stage I lung adenocarcinoma indicated that the low expression of
GalNAc-T3 was a significant independent factor for predicting poor prognosis and early recurrence (P¼0.006, rr¼2.87 and
P¼0.019, rr¼3.05, respectively). The low expression of GalNAc-T3 may be a useful marker for predicting poor prognosis and early
recurrence in completely resected lung carcinoma patients, particularly patients with stage I diseases.
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It is widely accepted that changes in the structure and distribution
of cell surface glycoproteins are assumed to influence the biologic
behaviour of tumour cells during malignant transformation and
tumour progression (Nakamori et al, 1994). In the past few years,
O-linked carbohydrate antigens, such as mucin antigen (MUC1),
carcinoembryonic antigen (CEA), sialyl LewisX (SLX), CA19-9,
Sialyl Tn (STn), and Tn have been reported to be associated with
altered adhesion (Fogel et al, 1983; Rice and Bevilacqua, 1989),
invasion (Bolscher et al, 1988; Matsushita et al, 1991; Nakamori
et al, 1994), recurrence, and prognosis (Itzkowitz et al, 1990;
Niklinski et al, 1992; Ogawa et al, 1994; Cao et al, 1995; Diez et al.,
1996; Ohgami et al, 1999) in lung cancer and other tumours.
Mucin-type O-linked carbohydrates may constitute up to 80% of
the total mass of these glycoproteins (Clausen and Bennett, 1996);
O-glycosylation has been shown to be important in the binding of
cell adhesion molecules, cell differentiation, invasion, and
metastasis in tumours (Nakamori et al, 1994; Clausen and Bennett,
1996; Sutherlin et al, 1997; Nomoto et al, 1999). Initial glycosyla-
tion of mucin-type O-linked protein was catalysed by a family of
the UDP-GalNAc: polypeptide N-acetyl-galactosaminyl trans-
ferases (GalNAc-transferase) (Hagen et al, 1993; Homa et al,
1993; Wandall et al, 1997). To date, seven distinct human GalNAc-
transferase genes (from GalNAc-T1 to GalNAc-T7) have been
cloned and characterised, and O-glycosylation is carried out in
part by the differential expression of GalNAc-transferase in normal
tissues and tumours (White et al, 1995; Bennett et al, 1996, 1998,
1999a,b; Wandall et al, 1997; Ten Hagen et al, 1998). Thus, the
differential expression of O-linked carbohydrate antigens in
tumours may be explained by the differential expression and
activity of specific GalNAc-transferases.
GalNAc-T3 expression is restricted to cell lines derived from
epithelial gland adenocarcinoma, but not cells derived from
nonsecretory epithelial tissue carcinomas (Sutherlin et al, 1997;
Nomoto et al, 1999). A recent study using a polyclonal antibody to
GalNAc-T3 demonstrated that GalNAc-T3 is expressed in adeno-
carcinoma but not nonadenocarcinoma cell lines (Nomoto et al.,
1999). Previous immunohistochemical results suggest that the
anti-GalNAc-T3 antibody may be useful for diagnostic purposes in
the early stages of breast cancer, but the relationship between
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with lung adenocarcinoma remains unknown.
This study was a retrospective cohort and designed to detect
GalNAc-T3 expression in lung adenocarcinoma by using immu-
nohistochemical staining, and to evaluate the relationship between
GalNAc-T3 expression levels and prognosis or recurrence of the
patients’ tumours.
MATERIALS AND METHODS
Patients and follow-up
We examined 148 of 184 (80.4%) consecutive patients with lung
adenocarcinoma, who underwent complete surgical resection
between July 1991 and September 1996 at the University of
Occupational and Environmental Health, School of Medicine,
Kitakyushu, Japan. The criteria for inclusion into the study were
based on the availability of follow-up data. Clinicopathological
data were obtained by retrospective chart review. Tumour stage
was classified according to Revisions in the International System
for Staging Lung Cancer (1997) (Mountain, 1997). There were 88
men and 60 women in this series, with a mean age of 64.8 years
(range, 32–84). None of these patients received chemotherapy or
radiotherapy prior to the operation. Of 148 (6.8%) patients, 10
received adjuvant chemotherapy and this adjuvant chemotherapy
does not affect the prognosis of these patients.
For the postoperative follow-up, the patients were examined
every month within the first year and at approximately 2- to 4-
month intervals thereafter. The evaluations included physical
examination, chest roentgenography, analysis of blood chemistry,
and carcinoembryonic antigen assay. Chest, abdominal, and brain
computed tomographic scans and a bone scintiscan were
performed every 6 months through the third year, and annually
thereafter. If any symptoms or signs of recurrence appeared in
these examinations, additional evaluations to locate the site of the
recurrence were performed. Survival data were updated in April
2001. Follow-up was available for all patients, ranging from 53 to
3507 days after the primary operation (median follow-up, 48.5
months).
Western blot analysis
Cytoplasmic proteins were extracted from the frozen normal tissue
and tumour tissue in adenocarcinoma patients and 5mg cytoplas-
mic proteins was electroblotted onto polyvinylidene difluoride
membranes (Immobilon; Millipore, Bedford, MA, USA) after
separation on 10% SDS–polyacrylamide gel electrophoresis gel.
Polyclonal antibody against GalNAc-T3 was generated by multiple
immunisations of a New Zealand white rabbit, using synthetic
peptides as described previously (Nomoto et al, 1999). Immuno-
blot analysis was performed with a 1:5000 dilution of anti-
GalNAc-T3 antibody. Detection was performed using ECL
(Amersham Pharmacia Biotech, Buckinghamshire, UK). High
GalNAc-T3 expression breast carcinoma given by Nomoto et al
(1999) was used as a positive control.
Immunohistochemical staining
A formalin-fixed, paraffin-embedded, 3-mm section was obtained
from each of the 148 samples of primary lesions. All specimens
were stained with haematoxylin and eosin for histopathologic
diagnosis. Immunohistochemical (IHC) staining was performed by
a streptavidin–biotin–peroxidase complex method (Nomoto et al,
1999). Sections were immersed briefly in a citrate buffer
(0.01molli
 1 citric acid: pH 6.0) and incubated for two 5-min
intervals at 1001C in a microwave oven for antigen retrieval. They
were then incubated with polyclonal GalNAc-T3 antibody diluted
1:2000 for 90min at room temperature by using the Labeled
Streptavidin Biotin kit (DAKO LSAB kit, CA930 13, Dako Corp.,
Carpinteria, CA, USA). Antibody was diluted in phosphate-
buffered saline (PBS) containing 2% bovine serum albumin
(BSA). High GalNAc-T3 expression breast carcinoma given by
Nomoto et al (1999) was also used as a positive control.
Immunostaining evaluation
All slides were evaluated for immunostaining by three observers
(CG, JL, and TO) using a blind protocol design (observers had no
information on clinical outcome or other clinicopathologic data).
Cells were judged positive for GalNAc-T3 when the cytoplasm or
cell membranes were stained. The percentage of positive cells was
calculated by counting more than 1000 cells in random high-power
fields (10 40), and scored according to the percentage of positive
GalNAc-T3 cells: score 0, 0–5%; score 1, 6–25%; score 2, 26–50%;
score 3, 51–75%; or score 4, 76–100% expression levels. To
evaluate the correlation with clinicopathological characteristics,
GalNAc-T3 expression scores were divided into two groups.
Specimens with expression scores of 0–2 were called low
expression of GalNAc-T3, and specimens with scores of 3–4 were
called high expression of GalNAc-T3.
Statistical analysis
The statistical significance was evaluated using the Pearson’s w
2
test. Survival curves were plotted according to the Kaplan–Meier
method (Kaplan and Meier, 1958), and differences between the
curves were analysed by the log-rank test (Peto et al, 1977). The
Cox proportional hazards model was applied to the multivariate
survival analysis (Cox, 1972). The results of the Cox proportional
hazards model did not seem to change when the follow-up was
within 5 years. Data were analysed with the use of Abacus
Concepts, Survival Tools for StatView (Abacus Concepts, Inc.,
Berkeley, CA, USA).
RESULTS
Western blot analysis
To determine the specificity of an anti-GalNAc-T3 antibody,
Western blot analysis was performed in 10 cases with frozen
normal tissue and tumour tissue from the same patient. GalNAc-
T3 expression was detected in 68kDa protein. High GalNAc-T3
expression breast carcinoma given by Nomoto et al (1999) was
used as a positive control (lane A). Figure 1 shows the one of
Western blotting analysis, in which samples were extracted from
normal tissue and tumour tissue of patients with well-differ-
entiated adenocarcinoma and poorly differentiated adenocarcino-
ma. GalNAc-T3 expression level of tumour tissue increased in
comparison with that of normal tissue in well-differentiated
adenocarcinoma, although the GalNAc-T3 expression level of
tumour tissue decreased in comparison with that of normal tissue
NT T N
well low
68 kDa
A
Figure 1 Western blotting analysis showed GalNAc-T3 expression
levels of normal tissue and tumour tissue of patients with well-differentiated
adenocarcinoma and poorly differentiated adenocarcinoma. Lane A;
positive control (extracted from high GalNAc-T3 expression breast
carcinoma), N; normal lung tissue, T; tumour tissue, well; well-differentiated
adenocarcinoma, poorly; poorly differentiated adenocarcinoma.
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between the results of Western blot analysis and the results of IHC
detection about GalNAc-T3 expression was 80%.
Immunohistochemical detection of GalNAc-T3 expression
in lung adenocarcinoma
In all 148 specimens, 69 (46.6%) stained positive for GalNAc-T3 in
the cytoplasm of over 50% of tumour cells, and 79 (53.4%) showed
a low expression of GalNAc-T3 in the cytoplasm. In tumour cells,
the GalNAc-T3 IHC staining was usually seen in the cytoplasm or
cell membranes. In a few cases, immunostaining was also observed
in the nucleus as well as in a chromosome in mitosis. But the
surrounding normal stromal cells did not react. In normal lung
tissues, GalNAc-T3 IHC staining was often seen in the respiratory
epithelium and bronchial glands. Typical appearances of staining
in high expression of GalNAc-T3 and low expression of GalNAc-T3
tumours are shown in Figure 2a and b, respectively. The relations
between GalNAc-T3 expression level and various clinicopathologic
characteristics of the patients are summarised in Table 1. The
frequency of low GalNAc-T3 expression was significantly lower in
well-differentiated adenocarcinomas (27.3%) than in those with
moderately and poorly differentiated adenocarcinomas (51.4 and
96.7%, respectively) (Po0.01). Thus, GalNAc-T3 expression in
tumours showed a significant relationship to histologic differ-
entiation. As shown in Table 1, low expression of GalNAc-T3 was
associated with pathologic stage (pStage) (Po0.01), lymph node
metastasis (Po0.01), and tumour recurrence (P¼0.016), but not
distant metastasis (P¼0.60). A borderline significant P-value was
also found in T status (P¼0.05).
Next, GalNAc-T3 expression level was compared to various
clinicopathologic parameters of patients with stage I lung
adenocarcinoma (tumours with no invasion of adjacent structures
and no metastases to regional lymph nodes or distant organs). As
shown in Table 2, among 78 patients with lung adnocarcinoma in
stage I, a significant relationship was observed between GalNAc-T3
expression and histologic differentiation. In addition, a low
expression of GalNAc-T3 was detected in 12 out of 21 (57.1%)
cases with recurrent disease, and this finding was statistically
significant (P¼0.02). Of the 12 patients, 10 experienced early
tumour recurrence (within 2 years of the primary operation).
Finally, the pattern of recurrence seemed to be haematogenous. In
all, 10 patients had haematogenous distant recurrences, one
patient had a lymphogenous recurrence, and one patient had
haematogenous recurrences in combination with lymphogenous
metastases. Thus, the low expression of GalNAc-T3 showed a
significant relationship to early tumour recurrence.
Influence of GalNAc-T3 expression level on survival and
recurrence
The influence of GalNAc-T3 expression level on the patients’
overall survival was evaluated. The overall 5-year survival rate was
47.4% for the 148 patients in this study. The Kaplan–Meier
survival curves demonstrated that the patients with low GalNAc-T3
expression had significantly shorter survival periods than those
Figure 2 GalNAc-T3 IHC detection in adenocarcinoma. (A) High
GalNAc-T3 expression tumour cells with deep brown stained cytoplasm
are shown in the case of well-differentiated adenocarcinoma (original
magnification  400). (B) Low GalNAc-T3 expression tumour cells
without stained cytoplasm are shown in the case of poorly differentiated
adenocarcinoma (original magnification  400).
Table 1 Relations between the level of GalNAC-T3 expression and
clinicopathologic characteristics in 148 lung adenocarcinoma
GalNAC-T3
Characteristics Total Low (%) High P
All cases 148 79 (53.4) 69
Gender
Male 88 54 (61.4) 34
Female 60 25 (41.7) 35 0.02
Age (years)
o65 68 42 (61.8) 26
Z65 80 37 (46.3) 43 0.06
Histologic Grade
Well 44 12 (27.3) 32
Moderately 74 38 (51.4) 36
Poorly 30 29 (96.7) 1 o0.01
Pathologic stage
1 78 28 (35.9) 50
2 9 4 (44.5) 5
3 53 42 (79.2) 11
4 8 5 (62.5) 3 o0.01
pTNM
T
T1 56 24 (42.9) 32
T2 51 26 (51.0) 25
T3 15 10 (66.7) 5
T4 26 19 (73.1) 7 0.05
N
N0 91 33 (36.3) 58
N1 14 10 (71.4) 4
N2 41 34 (82.9) 7
N3 2 2 (100) 0 o0.01
M
M0 140 74 (52.9) 66
M1 8 5 (62.5) 3 0.60
Recurrence
Without recurrence 106 50 (47.2) 56
With recurrence 42 29 (69.1) 13 0.02
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patients with low GalNAc-T3 expression (score 0 and 1) also had
significantly shorter survival periods than those with high GalNAc-
T3 expression (score 4) (Po0.01, data not shown) when the
survival curves of three groups patients were determined,
according to the cutoff points of 25 and 75%. Among the patients
with stage I (n¼78), the overall 5-year survival rates in the
patients with low GalNAc-T3 expression and high GalNAc-T3
expression were 41.6 and 82%, respectively (Po0.01) (Figure 3B).
In univariate analysis, six variables (gender, pT, pN, pM, grade of
differentiation, and high or low expression of GalNAc-T3) were
found significantly to affect survival in 148 adenocarcinoma
patients. Furthermore, a multivariate survival analysis demon-
strated that five variables (pT, pN, pM, grade of differentiation,
and high or low expression of GalNAc-T3) were independently
associated with patient survival (Table 3). The low expression of
GalNAc-T3 was estimated to be associated with an increased risk
of death by a factor of 2.22 in multivariate analysis (Po0.01). On
the other hand, in univariate analysis, three variables (pStage,
grade of differentiation, and high or low expression of GalNAc-T3)
were found to affect significantly survival in 78 patients with stage
I adenocarcinoma. Furthermore, a multivariate survival analysis
demonstrated that two variables (grade of differentiation, and high
or low expression of GalNAc-T3) were independently associated
with patient survival and low expression of GalNAc-T3 was
estimated to be associated with an increased risk of death by a
factor of 2.99 in multivariate analysis (Po0.01; data not shown).
To investigate whether GalNAc-T3 expression level is signifi-
cantly correlated with recurrence in early-stage diseases, disease-
free survival curves of the patients with GalNAc-T3 expression in
stage I were analysed using the Kaplan–Meier method. As shown
in Figure 4, the patients with low GalNAc-T3 expression had
significantly shorter disease-free survival periods than those with
high GalNAc-T3 expression (Po0.01). In univariate analysis, two
variables (grade of differentiation and high or low expression of
GalNAc-T3) were found to affect significantly disease-free survival
in 78 patients with stage I adenocarcinoma. The variable of pStage
was estimated as a borderline association (P¼0.06). A multivariate
diseade-free survival analysis demonstrated that the variable of
grade of high or low expression of GalNAc-T3 was independently
associated with disease-free survival. The low expression of
Table 2 Relations between the level of GalNAC-T3 expression and
clinicopathologic characteristics in stage I adenocarcinoma
GalNAC-T3
Characteristics n Low (%) High P
All cases 78 28 (35.9) 50
Histologic grade
Well 31 6 (19.4) 25
Moderately 38 14 (36.8) 24
Poorly 9 8 (88.9) 1 o0.01
Pathologic stage
1A 46 15 (32.6) 31
1B 32 13 (40.6) 19 0.47
Recurrence
Without recurrence 57 16 (28.1) 41
With recurrence 21 12 (57.1) 9 0.02
Years after operation
High GalNAc-T3 expression (n=69)
Low GalNAc-T3 expression (n=79)
P<0.01
A
0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8
Years after operation
P<0.01
B
0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8
High GalNAc-T3 expression (n=50)
Low GalNAc-T3 expression (n=28)
Figure 3 Survival curves of adenocarcinoma patients with low GalNAc-
T3 expression or high GalNAc-T3 expression. (A) Overall survival
(n¼148), the overall 5-year survival rates in the patients with low
GalNAc-T3 expression and high GalNAc-T3 expression were 25.4 and
72.1%, respectively (Po0.01). (B) Survival curves of stage I lung
adenocarcinoma patients (n¼78, Po0.01).
Table 3 Univariate and multivariate analyses using a proportional hazard
model for survival of 148 lung adenocarcinoma patients
Univariate analysis Multivariate analysis
Variable n 95% CI HR P 95% CI HR P
Gender
Female 60 1 1
Male 88 1.02–2.54 1.61 0.04 0.71–1.85 1.15 0.58
pT
T1 56 1 1
T2 51 1.39–4.45 2.49 o0.01 1.28–4.38 2.37 o0.01
T3 15 1.96–8.52 4.09 o0.01 1.06–5.37 2.38 0.04
T4 26 3.54–12.5 6.66 o0.01 2.16–8.72 4.34 o0.01
PN
N0 91 1 1
N1 14 1.86–6.94 3.59 o0.01 0.76–3.18 1.55 0.23
N2 41 2.31–5.98 3.71 o0.01 1.05–3.20 1.83 0.03
N3 2 1.23–21.7 5.17 0.03 2.46–59.1 12.1 o0.01
pM
M0 140 1 1
M1 8 1.85–9.26 4.13 o0.01 0.93–5.18 2.19 0.07
Grade
Well 44 1 1
Moderately 74 2.09–7.66 4.00 o0.01 1.46–6.07 2.98 o0.01
Poorly 30 2.11–9.37 4.44 o0.01 0.74–3.88 1.69 0.22
GalNAC-T3
High expression 69 1 1
Low expression 79 2.20–5.65 3.53 o0.01 1.26–3.91 2.22 o0.01
HR-hazard ratio.
GalNAc-T3 in lung adenocarcinoma
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of death by a factor of 3.05 in multivariate analysis (P¼0.02)
(Table 4).
DISCUSSION
Lung cancer is the leading cause of cancer-related deaths in North
America, and it became the most common cause of cancer-related
deaths among Japanese in 1998 (Ginsberg et al, 1997; Hara et al,
2000). Of the four main histologic types of lung cancer,
adenocarcinoma is the most commonly occurring type in Japan
(Hara et al, 2000). Lung cancer is also an aggressive carcinoma
with a poor outcome, and the overall 5-year survival rate is about
20% (Landis et al, 1998; Hara et al, 2000). Therefore, it is
important to evaluate the malignant potential of tumour cells for a
more precise evaluation of the prognosis for patients with lung
adenocarcinoma.
The current study investigated the associations between
GalNAc-T3 expression level and various clinicopathologic char-
acteristics of patients with lung adenocarcinoma. The low
expression of GalNAc-T3 was associated with poorly differentiated
tumour, poorly pathologic stage, lymph node metastasis and
tumour recurrence. Both univariate and multivariate analyses
demonstrated that, among the clinicopathologic factors examined,
low expression of GalNAc-T3 was a significant independent factor
for predicting poor prognosis and early recurrence.
Concerning the differentiation status of lung adenocarcinoma
and GalNAc-T3 expression levels, low expression levels of GalNAc-
T3 correlated with poorly differentiated adenocarcinoma and high
expression levels of GalNAc-T3 correlated with well-differentiated
adenocarcinoma. These findings are consistent with the report by
Sutherlin et al (1997) that GalNAc-T3 expression is higher in well-
differentiated pancreatic adenocarcinoma cell lines. Generally,
poorly differentiated adenocarcinoma are thought to have a greater
malignant potential than well-differentiated adenocarcinoma.
Thus, GalNAc-T3 expression level may be a marker of malignant
potential in lung adenocarcinoma.
It is well known that the metastatic process consists of several
stages: tumour cell escape from primary tumour, invasion of the
vessels, migration, adhesion to the vascular endothelium, extra-
vasation, and colonisation, all of which are essential for the
development of clinically overt metastases. Among O-linked
carbohydrate antigens, sialyl LewisX has been reported to function
as a ligand of the endothelial cell adhesion molecule E-selectin
(ELAM-1), which adheres human cancer cells to the vascular
endothelium (Phillips et al, 1990; Walz et al, 1990; Takada et al,
1993). In addition, a mucin antigen such as MUC1 inhibits the E-
cadherin-mediated cell–cell adhesion, which implies that MUC1
mucin enables adenocarcinoma cells to be detached readily from
the primary tumour tissue (Wesseling et al, 1996). MUC1
polypeptide is also associated with cell surface O-linked glycopro-
teins such as sialyl LewisX and sialyl LewisA (Ho et al, 1995). The
initial glycosylation of mucin-type O-linked carbohydrate antigens
is regulated in part by the differential expression of GalNAc-
transferase, which add GalNAc to fibronectine (Bennett et al.
1999b) and may affect the density or positions of attachment of O-
linked oligosaccharides (Sutherlin et al, 1997). Differential
expression of GalNAc-transferase may have a ‘valvular’ function
in regulating O-glycosylation in mucin-type O-linked carbohydrate
antigens such as sialyl LewisX and MUC1 (Wandall et al, 1997; von
Mensdorff-Pouilly et al, 2000). Therefore, GalNAc-transferase
expression may play a role in tumour cell escape from primary
tumour, adhesion to the vascular endothelium, and extravasation
during the metastatic process.
In lung cancer, even after a ‘curative’ resection for pathologic
stage I disease, about 30% of patients experience recurrence and
eventually die of the disease (Little et al, 1986; Ginsberg et al,
1997). This suggests that occult metastases are present at the time
of surgical intervention. Previous studies (Gu et al 2002) showed
that micrometastatic tumour cells (cytokeratin positive cells) were
present in pathologic negative lymph nodes in 34.7% of stage I
non-small-cell lung cancer (NSCLC) patients after complete
resectioning, and patients with micrometastatic tumour cells had
a poor prognosis and a high rate of recurrent disease. To see
whether GalNAc-T3 expression correlates with micrometastases,
micrometastatic tumour cells were detected in a total of 1436 hilar
and mediastinal pathologic negative lymph nodes from 65 patients
with stage I lung adenocarcinoma, using the method previously
described (Gu et al, 2002), Of 65 patients, 19 exhibited lymph
nodal micrometastasis, and a low expression of GalNAc-T3 was
found in 12 patients (63.2%) (P¼0.003). Furthermore, this may be
a partial explanation for the relationship between aberrant
expression of GalNAc-T3 and early metastasis (unpublished data,
with subjects different from those of this study). In the current
study, among 12 out of 78 patients with low GalNAc-T3 expression
and recurrent diseases in stage I lung adenocarcinoma, tumour
recurrence within 2 years of the primary operation was found in 10
patients. The pattern of recurrence seemed to be haematogenous,
and a low expression of GalNAc-T3 was associated with poor
prognosis and early recurrence. Based on these results, it is
P<0.01
Years after operation
0
0.2
0.4
0.6
0.8
1.0
0 2 4 6 8
Low GalNAc-T3 expression (n=28)
High GalNAc-T3 expression (n=50)
Figure 4 Disease-free survival curves of stage I lung adenocarcinoma
patients with low GalNAc-T3 expression or high GalNAc-T3 expression
(n¼78). The disease-free 3-year survival rates in the patients with low
GalNAc-T3 expression and high GalNAc-T3 expression were 59 and
87.9%, respectively (Po0.01).
Table 4 Univariate and multivariate analyses using a proportional hazard
model for disease-free survival of 78 patients with stage I adenocarcinoma
Univariate analysis Multivariate analysis
Variable n 95% CI HR P 95% CI HR P
pStage
1A 46 1 1
1B 32 0.96–5.43 2.29 0.06 0.83–5.01 2.04 0.12
Grade
Well 31 1 1
Moderately 38 1.12–10.3 3.40 0.03 0.87–8.39 2.70 0.09
Poorly 9 0.79–16.0 3.56 0.10 0.25–6.60 1.29 0.76
GalNAC-T3
High expression 50 1 1
Low expression 28 1.38–7.86 3.29 o0.01 1.22–7.65 3.05 0.02
HR¼hazard ratio.
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useful indicator of early tumour recurrence in stage I lung
adenocarcinoma.
In conclusion, low expression of GalNAc-T3 may be a useful
marker in predicting poor prognosis and early recurrence, not
only in all completely resected patients with adenocarcinoma
of the lung but also in those with stage I diseases. These patients
need to be followed up carefully after surgery. At present,
postoperative adjuvant chemotherapy is not a routine standard
therapy for completely resected NSCLC patients, because it has
not been shown to improve patient outcomes consistently.
However, by assessing the GalNAc-T3 expression level, it
would be possible to select patients who might benefit most from
adjuvant chemotherapy.
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